Stock Financial Ratios, Dividends, Split History

CAA / CalAtlantic Group, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price53.12
Volume17,976,300.00
Market Cap ($M)5,860.97
Book Value ($M)4,329.21
Book Value / Share39.24
Price / Book1.35
NCAV / Share-33.10
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 114,429,297
Weighted Average Number Of Diluted Shares Outstanding 135,984,985
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 114,472,916
Total Weighted Average Diluted Common Shares Outstanding 135,984,985
Weighted Average Number Of Shares Outstanding Basic 118,212,740
Total Weighted Average Common Shares Outstanding If Preferred Shares Converted To Common Shares 118,212,740
Scoring Models
Piotroski F-Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.06
Return on Assets (ROA)0.06
Return on Equity (ROE)0.13
Balance Sheet (mrq) ($M)
Assets9,079.03
Liabilities4,735.93
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Real Estate Revenue Net6,388,040,000.00
Home Building Revenue6,354,869,000.00
Financial Services Revenue88,695,000.00
Net Income484.73
Earnings Per Share Basic4.09
Earnings Per Share Diluted3.60
Cash Flow Statement (mra) ($M)
Cash From Operations322.31
Cash from Investing2.93
Cash from Financing2.93
Identifiers and Descriptors
CUSIP128195104
Central Index Key (CIK)878560
Related CUSIPS
85375C901 128195904 85375C951 128195954

Split History

Stock splits are used by CalAtlantic Group, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

9h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

Related News Stories

5 Factors That Underscore Lennar's (LEN) Solid Prospects

2018-07-02 zacks
Lennar Corporation’s (LEN - Free Report) shares have been rallying since the second-quarter fiscal 2018 release on Jun 26, 2018. In fact, the nation’s largest homebuilder has outperformed the homebuilding industry so far this year. Although Lennar deteriorated 17% year to date, it fared better than the broader industry’s 19.7% decline. Recently, Lennar posted stellar second-quarter results, surpassing the Zacks Consensus Estimate on both counts. (20-0)

Lennar (LEN) Q2 Earnings Beat on CalAtlantic Synergies

2018-06-26 zacks
Lennar Corporation’s (LEN - Free Report) shares have gained 7.5% in pre-market trading, after surpassing earnings as well as revenue expectations in the second quarter of fiscal 2018 – the first full quarter with CalAtlantic. The company’s second-quarter adjusted earnings of $1.58 per share surpassed the Zacks Consensus Estimate of 45 cents. The reported figure mainly excludes integration costs related to the acquisition of CalAtlantic Group, Inc. (25-0)

Lennar's (LEN) Q2 Earnings & Revenues Beat Estimates

2018-06-26 zacks
Lennar Corporation (LEN - Free Report) is one of the leading homebuilders in the United States. With overall housing market recovering at a slow but steady pace, Lennar's order trends have been improving at a consistent pace. Lennar is performing well on the back of its diverse revenue mix, large land supply, above average order growth and better pricing power. Investors should also note that 2018 earnings estimate for LEN has remained stable in the past 60 days. (19-0)

Will Higher Costs Weigh Down Lennar's (LEN) Q2 Earnings?

2018-06-25 zacks
Lennar Corporation (LEN - Free Report) is scheduled to announce second-quarter fiscal 2018 results on Jun 26, before the opening bell. Lennar has been showcasing solid top-line performances and the trend is supposed to continue in the soon-to-be-reported quarter as well, courtesy of robust demand for homes, favorable job market and impressive economic conditions. Let’s take a look at how the company's margin is shaping up for this earnings season. (20-0)

Zacks Industry Outlook Highlights: Lennar, M/I Homes and William Lyon Homes

2018-06-04 zacks
Chicago, IL – June 4, 2018 – Today, Zacks Equity Research discusses the Industry: Housing, Part 2, including Lennar (LEN - Free Report) , M/I Homes, Inc. (MHO - Free Report) and William Lyon Homes (WLH - Free Report) . (52-0)

CUSIP: 128195104